Here are four things to know:
1. Researchers conducted two randomized, controlled trials in which 28 case-series studies and five case reports were included.
2. Fecal microbiota transplantation was successful in 85 percent of recurrent CDI studies.
3. Fecal microbiota transplantation may have a substantial effect with few short-term adverse events for recurrent CDI, study authors concluded.
4. However, evidence is insufficient on fecal microbiota transplantation for refractory or initial CDI treatment, they note.
More articles on GI/endoscopy:
Dr. Richard Smith of Asheville Gastroenterology Associates to retire: 5 key notes
Ironwood Pharmaceuticals reports Q1 activity — 4 key updates
FDA holds further enrollment in GI Dynamics’ ENDO Trial: 4 things to know
